Teriparatida como tratamiento adyuvante en la osteonecrosis maxilar inducida por medicamentos
- José González Serrano
- Víctor Manuel Paredes Rodríguez
- Juan López-Quiles
- Gonzalo Hernández Vallejo
ISSN: 1697-6398, 1697-641X
Ano de publicación: 2015
Volume: 12
Número: 2
Páxinas: 35-38
Tipo: Artigo
Outras publicacións en: Científica dental: Revista científica de formación continuada
Resumo
The antiresorptive agents such as Denosumab, Raloxifene or bisphosphonates play a fundamental role in the treatment of bone diseases as osteoporosis. However, prolonged administration is associated with an increased risk of osteonecrosis of the jaws. Currently there is no effective and definitive treatment for this condition. For these reasons, new treatments capable of healing this disease are being sought. This paper aims to review teriparatide (human parathyroid hormone) as a new adjuvant treatment modality in patients with osteoporosis who suffer from medication-related osteonecrosis of the jaw (MRONJ). In several cases subcutaneous administration of 20µg/day of teriparatide has been used for healing bone necrosis. however, the current insufficient evidence requires the conduct of clinical trials evaluating teriparatide as an adjunctive treatment for MRONJ.